Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br AR expression in breast tissue Although
2024-02-07

AR expression in breast tissue Although androgenic signalling is chiefly associated with the development and maintenance of primary and secondary male characteristics, especially during puberty when the testes are by far the major source of testosterone, the AR also plays important functions in f
-
Based on their different sources the APN inhibitors APNIs ca
2024-02-07

Based on their different sources, the APN inhibitors (APNIs) can be divided into the natural products and synthetic compounds. Bestatin (1, Fig. 1), isolated from the Streptomyces oliuoreticuli by Umezawa et al., is the first reported and only marketed natural dipeptidomimetic inhibitor of APN. Afte
-
In this study we designed and synthesized
2024-02-07

In this study, we designed and synthesized two ALK PROTACs (degraders), 5 (MS4077) and 6 (MS4078), by linking ceritinib and pomalidomide [45] through two different linkers. Using human ALCL and NSCLC cells, we characterized both compounds in a battery of assays to demonstrate their effects on reduci
-
br Disclosures br Author contributions br Grants This work w
2024-02-07

Disclosures Author contributions Grants This work was supported by National Institutes of Health/National Heart, Lung, and Blood Institute MERIT Award R37 HL040696 to J.A.F. Acknowledgments Introduction The AGC kinases, named after the protein A, G and C kinases, are an evolutionaril
-
br Acknowledgements The authors would like to thank Dr Bradf
2024-02-07

Acknowledgements The authors would like to thank Dr. Bradford B. Lowell for providing us with β-less and WT breeding pairs. Funding sources: This work was supported by NIH Grant DK028082 (to E.M.F) and by an Institutional Research Training Grant NRSA 5T32DK751627 (to N.D.). Introduction The e
-
Mt a known to be upregulated by ozone
2024-02-07

Mt2a, known to be upregulated by ozone (Inoue et al., 2008), was also increased in vehicle-pretreated rats exposed to ozone, however, this effect was markedly reduced by both PROP and MIFE, suggesting that the neuroendocrine response is linked to ozone-induced acute phase protein expression. In huma
-
Adenosine A A agonists have been shown
2024-02-06

Adenosine A2A agonists have been shown to significantly reduce albuminuria in diabetic mice as well as plasma creatinine [24]. Proteinuria was greater in diabetic A2A knock-out (KO) mice than diabetic wild type (WT) mice [24]. Consistent with these findings, our laboratory initially found that prote
-
LDC000067 The first suggestions that the cleaved intracellul
2024-02-06

The first suggestions that the cleaved intracellular domain of APP, AICD, might transit to the nucleus and hence selectively regulate gene transcription arose from analogies with the Notch receptor signalling system where similar intra-membrane proteolysis occurs [84], [85] and it was later confirme
-
RWJ 56110 br Dual role of autophagy in human diseases Emergi
2024-02-06

Dual role of autophagy in human diseases Emerging evidence suggests that autophagy serves as a double-edged sword in several human diseases, such as CNS diseases (Rubinsztein et al., 2015), arteriosclerosis (Schrijvers et al., 2011) and cancer (Ozpolat and Benbrook, 2015). Likewise, currently the
-
Nowadays more than kinases have been identified of human gen
2024-02-06

Nowadays, more than 500 kinases have been identified of human genome [2]. Imatinib (Gleevec) was the first tyrosine kinase inhibitor approved by the US Food and Drug Administration (FDA) for the treatment of chronic myeloid leukemia [3], and kinases have become an attractive target for the developme
-
Nowadays more than kinases have been identified of human gen
2024-02-06

Nowadays, more than 500 kinases have been identified of human genome [2]. Imatinib (Gleevec) was the first tyrosine kinase inhibitor approved by the US Food and Drug Administration (FDA) for the treatment of chronic myeloid leukemia [3], and kinases have become an attractive target for the developme
-
s7694 br Experimental section br Competing interests br Auth
2024-02-05

Experimental section Competing interests Author's contributions Acknowledgement This research is partially supported by a seed fund for the Center for Drug Discovery and Translational Research (LS) and a research grant by Fujifilm (VPS and LS). The Sponsors played no roles in study desig
-
br Extracellular domain architecture The extracellular regio
2024-02-05

Extracellular domain architecture The extracellular region of GABAB receptor exists in a heterodimeric configuration regardless of interactions within the rest of the protein (Geng et al., 2012, Liu et al., 2004, Nomura et al., 2008). The extracellular domains of the GABAB1 and GABAB2 subunits ar
-
br ASK in multiple sclerosis and optic neuritis
2024-02-05

ASK1 in multiple sclerosis and optic neuritis Multiple sclerosis (MS), a chronic inflammatory demyelinating disease of the central nervous system (CNS), is the most common neurological disease among young adults in the United States and Europe (Dutta and Trapp, 2011). Although MS primarily affect
-
Since obesity appears to impact leptin and adiponectin
2024-02-05

Since obesity appears to impact leptin and adiponectin levels in opposite manners, several studies have suggested that the serum adiponectin/leptin ratio may be a key parameter in indicating the relative risk of postmenopausal breast cancer (Ollberding et al, 2013, Cleary et al, 2009). Therapeutic s
15485 records 163/1033 page Previous Next First page 上5页 161162163164165 下5页 Last page